StockGuru Profile

Skinvisible Launches DermSafe in Canada and Donates Product to the Canadian Olympic Foundation to Support Team Canada at the Olympic Games in Rio

Skinvisible Launches DermSafe in Canada and Donates Product to the Canadian Olympic Foundation to Support Team Canada at the Olympic Games in Rio

Protection is on its Way for Canadian Athletes

LAS VEGAS, NV and VANCOUVER, BC / ACCESSWIRE / July 26, 2016 / Skinvisible Inc., (SKVI), through its subsidiary Kintari Canada Inc., is proud to announce it has made a donation of DermSafe®, its non-alcohol hand sanitizer lotion, to the Canadian Olympic Foundation offering protection for Canada’s athletes during the upcoming Olympic Games in Rio. This coincides with Kintari’s launch of DermSafe in Canada.

DermSafe will be distributed to all Canadian athletes and coaches in Rio. Ken Dool, High Performance Director of Sail Canada expressed the importance of the product:

“DermSafe gives both the Canadian Sailing Team athletes and coaches confidence that we can safely approach both training and competition days with the knowledge that we are protected against environmental concerns arising from water quality. The product has proven to be exceptional under the rigours of training in Rio: to date both athletes and coaches have felt confident and protected, while having no side effects for either product use or the constant exposure to Rio’s water quality. Sail Canada thanks KINTARI, the producers of DermSafe for supporting our efforts in preparing to take on the world at the forth coming competitions in Rio.”

DermSafe is uniquely different than other hand sanitizers. It acts as a long-lasting protective barrier binding to the skin while actively combating the spread of germs between people and hard surfaces, or in this case infected water. It is a non-alcohol lotion made with 4% chlorhexidine gluconate (CHG), an ingredient which has demonstrated long-term persistence in its ability to kill both gram-negative and gram-positive bacteria and viruses. DermSafe has been successfully tested against a host of infectious germs including Methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli (E. coli).

“We were shocked to read that athletes were using alcohol hand sanitizer over their bodies after they came out of the water in Guanabara Bay to kill any germs that may be on their skin. Kintari wanted to help so we pledged a donation of DermSafe for all Canadian athletes, coaches and support staff,” said Terry Howlett, President of Kintari. “Kintari is proud to be involved and hopes that this contribution will help Canadian athletes in their quest for gold!”

Kintari thanks the Canadian Olympic Foundation’s airline partner Air Canada for their support in shipping the product to Rio.

For more information and how to purchase DermSafe PC contact Kintari at info@kintari.com or call toll free 1-844-KINTARI. DermSafe will also be available online in August at www.kintari.com select CANADA.

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a R&D company that licenses its proprietary formulations made with Invisicare®, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing skin irritation. Kintari Int. Inc., a wholly-owned subsidiary markets its cosmeceutical and OTC products.

www.skinvisible.com, www.invisicare.com, www.kintari.com

Forward-Looking Statements: This press release contains ‘forward looking’ statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the period ending March 31, 2016).

Corporate Contact:

Doreen McMorran, Skinvisible Inc.
Email: info@skinvisible.com
Phone: 702-433-7154

SOURCE: Skinvisible Inc.

.

John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.

Skinvisible Pharmaceuticals Inc.

OTCQB: SKVI

Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®.

Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products.

DISCLOSURE: John Pentony is a consultant to Skinvisible and is currently being paid nineteen hundred dollars for a program that covers the Company through January 18, 2017. There are no shares, warrants or other equity related compensation. Mr. Pentony previously represented Skinvisible Pharmaceuticals, Inc. as its investor relations coordinator internally. In the past John Pentony’s company was hired for the distribution of news and blogs about Skinvisible. John Pentony and any family member or associated companies do not hold shares, warrants or other positions in Skinvisible stock. In years past John Pentony’s company (Pentony Enterprise LLC / “PE”) has received a total of eight thousand in cash payments. In 2009 PE was compensated 500k shares of restricted stock.

Left Menu Icon
Right Menu Icon